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ABSTRACT
Objective The clinical utility of routine genetic 
sequencing in amyotrophic lateral sclerosis (ALS) is 
uncertain. Our aim was to determine whether routine 
targeted sequencing of 44 ALS- relevant genes would 
have a significant impact on disease subclassification 
and clinical care.
Methods We performed targeted sequencing of a 44- 
gene panel in a prospective case series of 100 patients 
with ALS recruited consecutively from the Sheffield 
Motor Neuron Disorders Clinic, UK. All participants 
were diagnosed with ALS by a specialist Consultant 
Neurologist. 7/100 patients had familial ALS, but the 
majority were apparently sporadic cases.
Results 21% of patients with ALS carried a confirmed 
pathogenic or likely pathogenic mutation, of whom 93% 
had no family history of ALS. 15% met the inclusion 
criteria for a current ALS genetic- therapy trial. 5/21 
patients with a pathogenic mutation had an additional 
variant of uncertain significance (VUS). An additional 
21% of patients with ALS carried a VUS in an ALS- 
associated gene. Overall, 13% of patients carried more 
than one genetic variant (pathogenic or VUS). Patients 
with ALS carrying two variants developed disease at a 
significantly earlier age compared with patients with 
a single variant (median age of onset=56 vs 60 years, 
p=0.0074).
Conclusions Routine screening for ALS- associated 
pathogenic mutations in a specialised ALS referral clinic 
will impact clinical care in 21% of cases. An additional 
21% of patients have variants in the ALS gene panel 
currently of unconfirmed significance after removing non- 
specific or predicted benign variants. Overall, variants 
within known ALS- linked genes are of potential clinical 
importance in 42% of patients.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult- 
onset neurodegenerative disease characterised by 
progressive injury and cell death of upper and lower 
motor neurons in the motor cortex, brainstem and 
spinal cord. This leads to progressive failure of the 
neuromuscular system with death, usually from 
respiratory failure, within 2–5 years of symptom 
onset in most cases. Up to 50% of cases also show 
mild cognitive impairment, with approximately 
5% progressing to clinically recognised fronto-
temporal dementia (FTD).1 While the majority of 
ALS cases are considered sporadic (sALS), 5%–10% 
have been shown to be familial, usually with auto-
somal dominant inheritance, and the genetic cause 
of approximately 60%–70% of familial ALS (fALS) 
cases has now been identified.2 The most common 
genetic cause of ALS is due to expansion of a 
GGGGCC (G4C2) hexanucleotide repeat in the 
first intron of the C9orf72 gene. This expansion 
has a frequency of 43% in fALS and 7% in sALS 
cases in our UK cohort,3 which is comparable with 
worldwide figures of 39.3% for fALS and 7.0% 
for sALS.4 Mutations in SOD1,5 6 TARDBP,5 7 8 and 
FUS5 9 genes, the next most common genetic causes 
of ALS, have also been reported in both patients 
with fALS and those with sALS. Therefore, it is clear 
that apparently sporadic cases can also carry poten-
tially pathogenic variants in known ALS genes. 
In a recent study which screened 17 ALS- related 
genes, 27.8% of apparently sporadic cases carried 
a potentially pathogenic or rare variant in a known 
ALS gene.10 In addition, it was noted that 3.8% of 
patients also carried multiple variants, with these 
cases having a significantly earlier age of onset. 
Another recent report from an Australian sporadic 
ALS cohort found that one- third of patients carried 
a variant of interest and 7% carried two or more 
variants, which again was correlated with an earlier 
age of onset.11 It has previously been reported that 
ALS is a six- step process, with genes, environment 
and time (in the form of ageing) contributing to 
disease development.12 It was proposed that indi-
viduals with a genetic variant would require fewer 
steps than those without such variants. Using data 
from an ALS registry in Italy, this proved to be the 
case, with individuals carrying C9orf72, TARDBP 
or SOD1 mutations showing a three- step, four- step 
and two- step process.13
Currently, only cases with a familial history of 
ALS, dementia or with a young age of disease onset 
tend to be routinely offered genetic screening in a 
clinical setting, at least in the UK.14 However, with 
the advent of therapies targeting specific genetic 
forms of the disease associated with SOD1 or 
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of BIIB067 and BIIB078), this raises the question as to whether 
all patients with ALS should be offered genetic screening.
Currently, only two neuroprotective therapies are available 
for patients with ALS, riluzole15 and edaravone16, and these 
agents have only very modest effects on the course of the disease. 
New approaches are required to improve outcomes in ALS clin-
ical trials and key to this is improved disease stratification, an 
approach which has been very successful in several areas of 
oncology.17
‘A Multi- Centre Biomarker Research Strategy in ALS’ 
(AMBRoSIA) is a longitudinal biosampling programme in which 
newly referred patients with ALS are approached for research 
participation. Consenting patients have genetic screening under-
taken on a research basis and samples of their blood, urine and 
cerebrospinal fluid are collected longitudinally, together with a 
skin biopsy for fibroblast culture and reprogramming. Here, we 
report our findings from the prospective genetic screening of a 
highly representative and deeply phenotyped cohort of patients 
with sporadic and familial ALS.
MATERIALS AND METHODS
Patient cohort and biosamples
The first 100 patients with clinically identified ALS (7 familial 
and 93 apparently sporadic) recruited to the Sheffield site of the 
AMBRoSIA programme were analysed in this study (table 1). 
The patients were recruited between June 2017 and October 
2019. Biosamples, including whole blood for DNA extraction, 
were obtained following informed written consent (REC 16/
LO/2136). Other than a confirmed diagnosis of ALS, no strict 
inclusion or exclusion criteria were adopted (see online supple-
mental table S5 for AMBRoSIA inclusion/exclusion criteria), so 
patients were not prioritised for genetic screening by clinicians. 
The diagnosis of ALS was made by an experienced neuromus-
cular neurologist (PJS, CJM, TMJ, CH) following appropriate 
investigations to exclude alternative diagnoses, and detailed clin-
ical and demographic features were recorded for all patients.
Illumina targeted panel sequencing
A panel of 44 ALS, motor system and FTD- linked genes 
(figure 1A) was screened to diagnostic standards using targeted 
next- generation sequencing by the UKAS- accredited Shef-
field Diagnostic Genetics Service laboratory, as part of the 
AMBRoSIA project. The panel was approved for familial ALS 
with and without FTD by the UK Genetic Testing Network 
steering group. DNA for the panel was captured using SureSe-
lectXT (Design ID: 0836801) automated library preparation and 
libraries were sequenced on an Illumina HiSeq 2500 in rapid 
run mode at 2×107 bp. A mean coverage of at least 100x was 
obtained (online supplemental figure S1).
C9ORF72 expansion testing
Hexanucleotide repeat expansions (G4C2) in C9ORF72 were 
tested by flanking PCR and, if required, fluorescent repeat 
primed PCR (RP- PCR) (online supplemental table S1). Fragment 
size analysis was performed in GeneMapper (V.3.5). Expansions 
were reported as normal if <30 repeats were detected, and all 
expansions of >30 repeats plus the classical sawtooth pattern 
were reported as potentially pathogenic.
ATXN2 expansion testing
ATXN2 repeat expansions (CAG) were tested by standard PCR 
with one fluorescently labelled primer (online supplemental table 
S2), followed by analysis using GeneMapper (V.3.5). ATXN2 
repeats were reported as normal between 14 and 28; 35 repeats 
and above were reported as consistent with spinocerebellar 
ataxia type 2 (SCA2) and repeat lengths of 29–34, which have 
been associated with an increased risk of ALS, were reported as 
intermediate repeat lengths.18
Sequencing and variant analysis
Sequencing data were analysed using a clinically validated 
bioinformatics pipeline. Samples were checked for contamina-
tion (online supplemental figure S2). Reads were aligned with 
bwa19 (V.0.7.15) to a bespoke version of the human reference 
(hg19). Indels were realigned with GATK20 (V.3.7). Variants 
were called with GATK Haplotype Caller (V.3.7) and decom-
posed and normalised with vt21 (V.0.5) and uploaded to Fabric 
Genomics Opal (V.6.1.8). Variants with a quality score <1500 
were excluded from further analysis. Protein coding variants, 
only, were retained.
The pathogenicity of a variant was determined using a multi-
faceted approach, including manual review in Opal, population 
frequency and in silico software algorithms, as well as the pres-
ence or absence of variants in our clinical reporting pipeline and 
the ALS literature.
Fabric Genomics Opal (V.6.1.8) provides population frequency 
from the 100,000 Genomes Project, Exome Variant Server of 
NHLBI GO Exome Sequencing Project, ExAC and gnomAD. We 
chose to report on overall population frequency using gnomAD, 
the largest dataset available.22
In silico analysis used the Omicia Score, which combines soft-
ware algorithms MutationTaster,23 Polymorphism Phenotyping 
v2 (PolyPhen2),24 Sorting Intolerant from Tolerant (SIFT)25 
and phyloP26—placental, primate and vertebrate. Additional 
Table 1 Cohort demographics and phenotypes
Total no of patients 100
Age (years), mean (range) 60.4 (22–87)
Male 54%
Female 46%
Site of first muscle weakness
  Upper limb 40%
  Lower limb 39%
  Bulbar 19%
  Respiratory 1%
  Trunk 1%
Disease subtype
  ALS 83%
  LMN predominant 12%
  UMN predominant 5%
Family history of ALS 7%
Time from onset of first muscle weakness (months), 
mean (SD, range)
20.8 (20.4, 1–134)
Time from onset of first muscle weakness until death 
(months), mean (SD, range)*
28.5 (21.0, 7–85)
ALSFRS- R, mean (range) at first assessment 36.9 (15–47)
Revised El- Escorial criteria at first assessment
  Clinically probable laboratory supported 36%
  Clinically probable 30%
  Clinically suspected 15%
  Clinically definite 13%
  Clinically possible 6%
ALS, amyotrophic lateral sclerosis; ALSFRS- R, revised ALS- Functional Rating Score; 
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algorithms used were VAAST Variant Prioritization (VVP) and 
Combined Annotation Dependent Depletion (CADD).27 Classi-
fication of variant effects was based on transcripts detailed in 
online supplemental table S3. Potential splicing disruption was 
predicted using Neural Network Splice (NNSplice),28 Gene-
Splicer29 and MaxEntScan.30
The ClinVar database (2 January 201931) was also used to deter-
mine if the variant had been previously assessed. Variants previ-
ously described as pathogenic or likely pathogenic in Opal, the 
genetics service clinical pipeline, or the literature (based ClinVar) 
were labelled as such. Variants with a lesser likelihood of patho-
genicity were labelled as benign and excluded from reporting if 
Figure 1 Clinical screening of all patients with ALS identifies pathogenic, likely pathogenic and variants of uncertain significance (VUS). (A) The 44 genes 
covered by the clinical ALS panel (42 profiled by next- generation sequencing and 2 by PCR). Those genes in which pathogenic (red), likely pathogenic 
variants (orange) or VUS (blue) were identified after filtering. No pathogenic variants or VUS were found in the genes depicted in the white boxes. 
Background colour of the box represents the most severe variant found in that gene. (B) Schematic of our variant analysis and filtering process. (C) Counts 
of reportable (red) and variants of unknown significance in ALS genes in the Sheffield AMBRoSIA cohort. (D) Five clinically reportable variants in SOD1. (E) 4 
Variants of unknown significance were discovered in SPG11. Interestingly, 3 of these cluster in the C- terminal domain. Benign and likely benign mutations 
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they had one of the following properties: (1) intronic or synon-
ymous variants with no predicted effect on splice sites; (2) an 
allele frequency >0.001 according to gnomAD22; (3) previously 
reported as benign in ClinVar; (4) a CADD score <15.27 Vari-
ants of uncertain significance (VUS) were determined as those 
that did not fit the aforementioned criteria for pathogenic/likely 
pathogenic or benign. CADD score is not available for indels and 
therefore indels were denoted as VUS if minor allele frequency 
(MAF) <0.001 and they passed following QC criteria: Quality 
Depth (QD) <2, Fisher Strand (FS) >200, ReadPosRankSum 
<−20 (n=43) and if the frequency in the present cohort was 
<0.1 (n=23). Those that are >0.001 in gnomAD (n=20) and 
non- coding indels were removed (n=13). Finally, we removed 
those that were common in controls in ProjectMine (see online 
supplemental table S4 for details of the ProjectMine sequencing 
consortium), leaving 11 indels (online supplemental figures S3 
and S4).
RESULTS
Prospective genetic testing leads to identification of clinically 
reportable pathogenic mutations
We profiled a panel of 44 relevant genes (figure 1A) in 100 
prospectively identified patients with ALS using Best Practice 
NHS pipelines.32 In 21 patients (21%), we identified 22 clinically 
reportable pathogenic and likely pathogenic variants (table 2 and 
figure 1B,C). Seven of the 21 patients reported a family history 
of ALS in a first- degree relative, but 14 patients with a clinically 
reportable pathogenic mutation had apparently sporadic disease.
As expected, the most frequently identified pathogenic muta-
tion was in C9ORF72 in 10 patients with ALS (10% of the 
cohort).3 Three of these patients had reported a family history 
of ALS. We identified five patients (5% of the cohort) each with 
a clinically reportable SOD1 mutation (table 2 and figure 1D), 
four of whom had a family history of ALS. Identification of 
C9ORF72 and SOD1 mutations is particularly important 
because these genes are associated with ongoing genetic- therapy 
trials (Biogen BIIB067 and BIIB078).
We identified two patients with sporadic ALS with clinically 
reportable changes in FIG4: p.Ile41Thr and p.Thr689Asnf-
sTer12 (table 2). The p.Ile41Thr mutation is reported as patho-
genic in ClinVar, with no conflicts. The p.Thr689AsnfsTer12 
variant has been reported twice before and only in sporadic ALS, 
suggesting variable penetrance. A frameshift mutation is likely 
to lead to haploinsufficiency (online supplemental figure S5). 
FIG4 variants are thought to disrupt local folding of the protein 
leading to a reduction in stability which inhibits the normal func-
tion of the protein in lysosomal trafficking.33
Four additional mutations in three patients were identified 
which were classified as clinically reportable (table 2). A single 
patient with sALS carried a p.Pro777Leu NEFH mutation and 
a p.Thr293IIe ALS2 mutation. The p.Thr293Ile change was 
heterozygous, whereas ALS2 mutations are usually considered 
to be autosomal recessive.34 As a result, the clinical significance 
of this finding is currently uncertain. However, it is possible that 
the two identified changes act synergistically. A single patient 
harboured a p.Ala2338Val SPG11 mutation and a further single 
patient carried an inframe deletion within TBK1 p.Glu643del. 
SPG11 mutations are usually considered to be recessive and 
therefore the clinical significance of this finding is at present 
uncertain. The TBK1 change is reported in ClinVar as patho-
genic. We identified one patient with an expansion of 29 CAG 
repeats in the ATXN2 gene which has been reported as a risk 
factor for ALS.18 The majority of cases in this cohort had 22 or 
23 repeats (range 15–29).
Panel screening leads to identification of VUS
Thirty- four variants in 26 patients with ALS (3 familial and 23 
sporadic) (26%) were reported in ClinVar as of uncertain signifi-
cance, or absent from ClinVar and met our criteria for predicted 
Table 2 Clinically established and ACMG reportable variants in ALS- associated genes: 22 changes in 21 individuals
Sample Gene Genomic variant Protein change (HGVSp canonical) Population frequency (gnomAD) Classification
SHF-094 ALS2 chr2:g.202625839G>A p.Thr293Ile 1.00E−05 Pathogenic
SHF-014 C9orf72 – – NA Pathogenic
SHF-017 C9orf72 – – NA Pathogenic
SHF-018 C9orf72 – – NA Pathogenic
SHF-043 C9orf72 – – NA Pathogenic
SHF-081 C9orf72 – – NA Pathogenic
SHF-083 C9orf72 – – NA Pathogenic
SHF-103 C9orf72 – – NA Pathogenic
SHF-138 C9orf72 – – NA Pathogenic
SHF-152 C9orf72 – – NA Pathogenic
SHF-162 C9orf72 – – NA Pathogenic
SHF-021 ATXN2 – – NA Likely pathogenic
SHF-065 FIG4 chr6:g.110107620T>TA p.Thr689AsnfsTer12 None Likely pathogenic
SHF-080 FIG4 chr6:g.110036336T>C p.Ile41Thr 0.00102 Pathogenic
SHF-094 NEFH chr22:g.29885959C>T p.Pro777Leu 3.00E−05 Pathogenic
SHF-006 SOD1 chr21:g.33039672T>C p.Ile114Thr 5.00E−05 Pathogenic
SHF-039 SOD1 chr21:g.33039672T>C p.Ile114Thr 5.00E−05 Pathogenic
SHF-078 SOD1 chr21:g.33039672T>C p.Ile114Thr 5.00E−05 Pathogenic
SHF-082 SOD1 chr21:g.33040846C>A p.Asn140Lys 0 Pathogenic
SHF-007 SOD1 chr21:g.33038821G>T p.Asp77Tyr None Pathogenic
SHF-085 SPG11 chr15:g.44856883G>A p.Ala2338Val 1.00E−05 Likely pathogenic
SHF-084 TBK1 chr12:g.64891000TGAA>T p.Glu643del 1.00E−05 Likely pathogenic
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pathogenic variants (table 3). Also, 5/26 patients with a VUS had 
an additional pathogenic variant.
Without pedigree information or population- matched 
controls, it is difficult to conclusively demonstrate pathogenicity. 
ALS has a polygenic rare variant architecture and therefore we 
filtered for rare predicted pathogenic variants which we quan-
tified as MAF <0.001 and CADD >1527 (online supplemental 
figure S3). In addition, we used population- matched whole 
genome sequencing data from 5954 patients with ALS and 
2238 controls included in Project MinE35 to check for evidence 
of pathogenicity based on case:control ratio (Fisher exact test 
p≤0.05). VUS were excluded from further analysis if they were 
not significantly associated with ALS in population- matched 
data, unless low frequency within the whole genome sequencing 
dataset (<10 individuals) prevented conclusive testing.
For each identified VUS, we performed a literature search to 
explore the case that this was indeed a newly identified ALS- 
risk variant. In particular, we sought evidence that a discov-
ered VUS was present within the same functional domain as 
described pathogenic variants: for TBK1, NEK1 and FIG4 this 
included nonsense and frameshift changes because pathogenic 
changes in these three genes are thought to act via loss of 
function.33 36 Based on these criteria, we conclude that the 
following VUS are likely to be pathogenic: p.Met405Val and 
p.Met322Val within TARDBP; p.Met459Thr in EWSR1; p.Gl-
n1034Ter and c.1665+2T>C in NEK1; p.Arg2318Cys and 
p.Ile2246Thr in SPG11. Our data are suggestive of patho-
genicity, but confirmations will require further validation by 
future studies.
Indels have high rates of inaccurate sequencing. We removed 
all non- coding indels, those with low quality and those present 
in >10% of this cohort and present in Project MinE controls 
leaving two frameshift variants, seven inframe deletions and two 
splice region variants. FIG4 has a frameshift in codon 689 which 
has not previously been reported in gnomAD (V.2.1.1—online 
supplemental figure S5) and SPG20 has a frameshift close to the 
end of the protein at codon 1969 which has a very low popu-
lation frequency (0.0000636—online supplemental figure S6). 
TBK1 has an inframe deletion of a single codon, which has previ-
ously been reported in ClinVar as pathogenic (online supple-
mental figure S7).
Table 3 Variants of unconfirmed significance with potential for pathogenicity in ALS- associated genes
Sample Gene Genomic variant






SHF-029 ALS2 chr2:g.202626478C>T p.Ser80Asn None 15.15
SHF-147 ALS2 chr2:g.202609025A>G p.Leu709Pro None 28.9
SHF-082 ANXA11 chr10:g.81930624G>C p.Pro35Ala 0.00012 22.4
SHF-139 ARHGEF28 chr5:g.73181708C>T p.Ala1030Val 7.00E−05 28.5
SHF-159 ARHGEF28 chr5:g.73200229A>T p.Gln1387Leu None 34
SHF-110 ATXN2 chr12:g.112036798TGCTGCTGCTGCTGCTGCTGC>T p.Gln168AlafsTer75 2.00E−05
SHF-129 CHMP2B chr3:g.87289902A>G p.Arg30Gly 0.00013 26
SHF-035 DCTN1 chr2:g.74597128C>G p.Glu452Asp None 25.9
SHF-127 DCTN1 chr2:g.74594023G>A p.Arg785Trp 0.00018 32
SHF-095 ERBB4 chr2:g.212566786G>T p.Asn465Lys 9.00E−05 17.1
SHF-159 EWSR1 chr22:g.29693883T>C p.Met459Thr 1.00E−05 22.6
SHF-157 KIF5A chr12:g.57970115C>T p.Arg718Trp None 27.3
SHF-062 KIF5A chr12:g.57957406T>C p.Val74Ala None 26.2
SHF-097 NEK1 chr4:g.170398474A>C p.Asn745Lys 0.00481 26.5
SHF-144 NEK1 chr4:g.170345826G>A p.Gln1034Ter None 35
SHF-138 NEK1 chr4:g.170458958A>G c.1665+2T>C 1.00E−05 29.7
SHF-128 NEK1 chr4:g.170506573T>G p.Asp245Ala None 23
SHF-146 SETX chr9:g.135205481G>A p.Arg502Trp 0.00049 27.7
SHF-162 SETX chr9:g.135211865C>T p.Gly179Glu 0 26.6
SHF-009 SPAST chr2:g.32289207T>TCGGCCC p.Ala106_Pro107dup 3.00E−05 16.17
SHF-114 SPG11 chr15:g.44914544A>C p.Val773Gly 0.00012 28.9
SHF-139 SPG11 chr15:g.44858099G>A p.Arg2318Cys 3.00E−05 23.2
SHF-009 SPG11 chr15:g.44859639A>G p.Ile2246Thr 3.00E−05 29.4
SHF-148 SPG20 chr13:g.36878530ACTTC>A p.Glu657Ter 6.00E−05 23.5
SHF-057 SQSTM1 chr5:g.179250020G>A p.Val90Met 4.00E−05 21.9
SHF-009 TAF15 chr17:g.34171988G>A p.Arg562Gln 2.00E−05 18.24
SHF-029 TAF15 chr17:g.34171971CGGCTATGGAGGAGACCGAGGTGGG>C p.Gly565_Gly572del 0.0001 20.9
SHF-092 TAF15 chr17:g.34171575GGGTGGCTATGGTGGAGACAGAAGCAGC>G p.Tyr427_Gly435del 2.00E−05 21.6
SHF-103 TAF15 chr17:g.34149811G>A p.Arg153Lys 1.00E−05 24.3
SHF-014 TARDBP chr1:g.11082679A>G p.Met405Val 0 21.9
SHF-062 TARDBP chr1:g.11082430A>G p.Met322Val 0 22.4
SHF-128 VAPB chr20:g.56993275A>G p.Thr23Ala 0 23.7
SHF-144 VPS54 chr2:g.64171737A>G p.Val433Ala None 18.2
SHF-141 VPS54 chr2:g.64189223G>C p.Gln327Glu 1.00E−05 24.1
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Panel genes where no changes were found
For 20 (highlighted in figure 1A) of the 44 genes screened in our 
panel, no mutations (pathogenic or VUS) were identified in any 
member of our cohort. Many of these genetic changes are indi-
vidually rare and our data are consistent with this. The absence 
of identified VUS in patients with sporadic ALS would be consis-
tent with a model in which these genes harbour only high- effect, 
highly penetrant mutations.
Clinical correlation supports pathogenicity of VUS
In the absence of experimental validation, the biological effect 
of genetic variation can be inferred from correlation with clin-
ical phenotype. The number of clinically reportable variants and 
VUS were combined to assign a ‘mutation- load’ to 42 patients 
with ALS (figure 2A). Patients with ALS without discovered vari-
ants were excluded because of absent information. To determine 
whether mutation load was clinically relevant, we compared 
age of onset between patients with one or two variants. Patients 
with ALS carrying two variants (n=13) compared with one 
variant developed disease at a significantly earlier age (log- rank 
test, p=0.0074, median age of onset=56 years vs 60 years, 
figure 2B,C). It is not yet possible to assess any potential effect 
on disease duration because 67% of this cohort are still living. 
Correlation with clinical phenotype is therefore consistent with 
a functional effect of both clinically reportable genetic variants 
and VUS.
DISCUSSION
An important strength of our study is its prospective nature. We 
performed targeted sequencing of ALS- relevant genes in 100 
prospectively identified patients with ALS attending a large ALS 
centre in Northern England. This identified clinically reportable 
genetic changes in 21% of patients of whom 15 with C9ORF72 
or SOD1 mutations would potentially be eligible for recruitment 
into an ongoing genetic- therapy trial. The number of clinically 
actionable results is likely to increase with the anticipated devel-
opment of new genetic- therapy approaches for ALS. Previous 
genetic studies of ALS have been largely retrospective and were 
therefore unable to determine the utility of genetic screening 
in the clinic. In contrast, the present study strongly suggests 
that routine genetic testing should be offered in both patients 
with familial ALS and those with sporadic ALS, at least in our 
population.
Figure 2 Increased mutation burden is associated with earlier age at onset. (A) Details of patients with two or more pathogenic, likely pathogenic or 
variants of uncertain significance (VUS) (n=13). (B) The number of pathogenic, likely pathogenic and VUS in each patient in the study. (C) Cumulative event 
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We identified 22 clinically reportable mutations and 34 VUS 
with potential for pathogenicity in 42 patients, including 35 
patients with apparently sporadic ALS. Moreover, we iden-
tified a strong correlation between mutation load and age of 
onset, suggesting that the majority of the VUS may be function-
ally important. Evaluation of the pathogenicity of individual 
VUS requires further study, but comparison with previously 
described variants in the literature suggests that we have iden-
tified novel likely pathogenic changes in TARDBP (two vari-
ants), EWSR1, SPG11 (two changes) and NEK1 (two variants). 
Genetic changes were absent from 20 genes in the panel in this 
cohort (figure 1A).
Mutations in RNA binding proteins are significantly asso-
ciated with ALS.37 Most prominently, TARDBP encodes the 
protein TDP-43 which is the major component of the character-
istic proteinopathy in ALS. Pathogenic mutations are clustered 
in the C- terminal glycine- rich domain which is important for 
interactions with other RNA- binding proteins.38 We have identi-
fied two patients with rare and predicted deleterious mutations 
in TARDBP which are both located in the glycine- rich domain 
(table 3 and online supplemental figure S8). Both changes 
(p.Met322Val and p.Met405Val) are absent from 125 748 popu-
lation controls in gnomAD and are predicted deleterious (CADD 
>15), although neither has been previously reported. FET 
proteins including EWSR1, FUS and TAF15 are RNA- binding 
proteins which have been associated with fALS. We identified 
several VUS within FET proteins with some evidence for patho-
genicity (table 3). One patient carried a p.Met459Thr EWSR1 
mutation within the RNA binding region which contains other 
ALS- associated mutations.
We identified four variants within SPG11 (figure 1E): one clin-
ically reportable change plus two of the VUS. All four variants 
cluster in the spatacsin C- terminal domain, suggesting that this 
could represent a region of functional importance. Conversely, 
benign mutations in this gene tend to be more dispersed and 
none are found in the spatacsin C- terminal domain. We conclude 
that the two p.Ile2246Thr and p.Arg2318Cys VUS we identified 
are highly likely to be pathogenic.
Mutations in TBK1,36 NEK139 and FIG433 have conclusively 
been shown to be loss of function (LOF) changes. In our cohort, 
we identified two VUS within NEK1 which significantly disrupt 
the translated sequence and are therefore predicted to be highly 
pathogenic via a LOF mechanism (online supplemental figure 
S8). This included p.Gln1034Ter and c.1665+2T>C which is 
a splice site mutation. Both mutations are rare or absent from 
gnomAD and are predicted pathogenic (table 3). Similarly, we 
identified a clinically reportable frameshift mutation in FIG4 
(p.Thr689AsnfsTer12- FIG4) and an in- frame deletion in TBK1 
(p.Glu643del- TBK1) which has previously been reported in 
a single case in ClinVar (online supplemental figure S7). Our 
data add to the weight of evidence that this change is pathogenic 
and that mutations in TBK1 are an important contributor to the 
genetics of sporadic ALS.39
VUS were identified based on universal measures of patho-
genicity 27 and population frequency.22 However, we added an 
additional filtering step based on case:control ratio within a 
population- matched whole genome sequencing dataset.35 When 
combined with clinically reportable changes, the resulting VUS 
were associated with age of onset which suggests that these are 
likely to represent pathogenic changes. We confirmed previous 
reports that C9ORF72 expansions are frequently associated with 
additional likely pathogenic mutations in other ALS genes.40 In 
the present cohort, 40% of patients with pathogenic C9ORF72 
expansions carried an additional VUS. The presence of such 
an additional genetic variant may be one factor influencing the 
penetrance of C9ORF72 mutations.
The current model of ALS is considered a multistep process 
in which steps constitute genetic and/or environmental expo-
sures.12 A consistent finding in ALS genetics is that identifica-
tion of a highly penetrant genetic risk factor correlates with 
earlier age of onset. It follows that such mutations might be 
associated with fewer steps and this has been supported.13 Our 
work suggests that, when correctly prioritised, VUS can also 
contribute steps leading to earlier age of onset and potentially 
function as a prognostic biomarker. Similar findings have been 
reported previously10 but not in a prospective cohort; moreover, 
the latter study was limited to a smaller number of genes. If an 
index case carries one or more VUS within ALS- linked genes, 
then screening for VUS within family members may inform risk 
and even age of onset counselling. In the present cohort, an addi-
tional VUS was associated with ~4 years earlier age of onset.
In conclusion, we have performed a prospective genetic study 
of 100 consecutive patients with ALS attending our clinic. Our 
results indicate that screening of known ALS genes can lead 
to clinically actionable results in ~21% of patients, and in a 
further ~21% of patients a VUS may be discovered with poten-
tial clinical implications. As future studies expand the number 
of verified genetic causes of ALS, these percentages are likely 
to increase. We developed a pipeline for prioritising VUS using 
whole genome case–control cohorts to predict clinical outcomes. 
Although this study took place in a large tertiary referral ALS 
centre and requires further validation in other settings, our data 
suggest that all patients with ALS should, with careful counsel-
ling, be offered genetic testing, especially in light of new person-
alised medicine treatments in development.
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Sizing (standard) primers: 
C9ORF72-F FAM-CAA GGA GGG AAA CAA CCG CAG CC 
C9ORF72-R GCA GGC ACC GCA ACC GCA G 
Repeat primed-PCR primers: 
MRX-F FAM-TGT AAA ACG ACG GCC AGT CAA GGA GGG AAA 
CAA CCG CAG CC 
MRX-M13R CAG GAA ACA GCT ATG ACC 
MRX-R1 CAG GAA ACA GCT ATG ACC GGG CCC GCC CCG ACC 
ACG CCC CGG CCC CGG CCC CGG 
 





SCA2F-FAM FAM-GGG CCC CTC ACC ATG TCG 
SCA2R CGG GCT TGC CCA CAT TGG 
 
Supplementary Table S2   Primers used for standard PCR of ATXN2 repeat expansions. 
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Gene RefSeq Transcript Gene RefSeq Transcript 
CHMP2B NM_014043.3 MATR3 NM_199189.2 
CYP27A1 NM_000784.3 NEFH NM_021076.3 
DCTN1 NM_004082.4 NEK1 NM_001199397.1 
GRN NM_002087.3 OPTN NM_001008211.1 
MAPT NM_005910.5 PFN1 NM_005022.3 
SPG11 NM_025137.1 PRPH NM_006262.3 
ALS2 NM_020919.3 SETX NM_015046.5 
ANG NM_001145.4 SIGMAR1 NM_005866.3 
ANXA11 NM_145869.1 SOD1 NM_000454.4 
ARHGEF28 NM_001080479.2 SPAST NM_014946.3 
ATXN2 NM_002973.3 SPG20 NM_015087.4 
C9orf72 NM_001256054.2 SQSTM1 NM_003900.4 
CHCHD10 NM_213720.2 SS18L1 NM_198935.2 
DAO NM_001917.4 TAF15 NM_139215.2 
ERBB4 NM_005235.2 TARDBP NM_007375.3 
EWSR1 NM_013986.3 TBK1 NM_013254.3 
FIG4 NM_014845.5 TUBA4A NM_006000.2 
FUS NM_004960.3 UBQLN2 NM_013444.3 
GBA2 NM_020944.2 VAPB NM_004738.4 
HNRNPA1 NM_031157.2 VCP NM_007126.3 
HNRNPA2B1 NM_031243.2 VPS54 NM_016516.2 
KIF5A NM_004984.2 VRK1 NM_003384.2 
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Supplementary Table S5.  Inclusion and exclusion criteria for the 




For all participants: 
• Age>18 
• Participant is willing and able to give informed consent for participation in the study, or 
an appropriate consultee can be identified to provide advice about his/her friend or 
relative’s inclusion in the study. If the participant is unable to provide written consent 
due to physical disability, an independent witness will be present at the informed 
consent discussion and sign the consent form on the participant’s behalf. 
Additional criterion for patients with MND only: 
• Diagnosis made by experienced neurologist. 
Additional criterion for family members of patients with MND only: 
• Known to have an MND gene mutation, or is a genetic relative of an affected MND or 
FTD patient.  
Additional criterion for patients with other neurological conditions only: 
• Diagnosis by a neurologist of another neurological condition, for example, Kennedy's 





The participant may not enter the study if ANY of the following apply: 
• Age <18 years 
• Pregnancy or any other condition that in the opinion of the investigator could interfere 
with the interpretation of the study results. 
In addition to the general inclusion/exclusion criteria described above, the additional 
exclusion criteria apply for invasive procedures (skin biopsy and lumbar puncture): 
• Significant bleeding diathesis or sepsis, or other condition that in the opinion of the 
investigator could constitute a health risk to the participant if he/she took part in this 
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Supplementary Figure S1   Gene Panel Coverage 
A. Mean coverage across the targeted region of the panel, error bars represent standard deviation. 
B. Percentage of targeted bases that are covered at greater than or equal to 100x. C. Percentage 
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Supplementary Figure S2   Contamination Estimate 
Samples are routinely checked for contamination as part of the clinical diagnostics pipeline using 
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Supplementary Figure S5 FIG4 Frameshift Variant 
A. Raw sequencing reads from SHF-065 show the presence of a heterozygous insertion in codon 
689 of FIG4 (NM_014845). B. Position of the frameshift mutation detected in the AMBRoSIA 
cohort vs the 5 frameshift variants present in ClinVar at the time of writing, 4/5 are classed as 
pathogenic. 
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Supplementary Figure S6 SPG20 Frameshift Variant 
A. Raw sequencing reads from SHF-148 show the presence of a heterozygous deletion in codon 
657 of SPG20 (NM_015087). B. Position of the frameshift mutation detected in the AMBRoSIA 
cohort vs the 4 frameshift variants present in ClinVar at the time of writing, 3/4 are classed as 
pathogenic. 
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Supplementary Figure S7 TBK1 Inframe Deletion Variant 
A. IGV plot showing a heterozygous 3bp deletion in codon 641 of TBK1. B. ProteinPaint of the 
TBK1 protein showing the deletion detected in this dataset (top) compared to deletions detected in 
ClinVar (bottom). Deletion in AMBRoSIA cohort is at the same position as a reported pathogenic 
mutation in ClinVar. 
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Supplementary Figure S8 Additional ProteinPaints of genes implicated in ALS 
Genes with at least 2 variants not already included in the manuscript and predicted to be 
Pathogenic/Likely Pathogenic or VUS were chosen for display here (excluding expansions). 
ProteinPaints were produced using https://pecan.stjude.cloud/proteinpaint and edited in Adobe 
Illustrator. 
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Sizing (standard) primers: 
C9ORF72-F FAM-CAA GGA GGG AAA CAA CCG CAG CC 
C9ORF72-R GCA GGC ACC GCA ACC GCA G 
Repeat primed-PCR primers: 
MRX-F FAM-TGT AAA ACG ACG GCC AGT CAA GGA GGG AAA 
CAA CCG CAG CC 
MRX-M13R CAG GAA ACA GCT ATG ACC 
MRX-R1 CAG GAA ACA GCT ATG ACC GGG CCC GCC CCG ACC 
ACG CCC CGG CCC CGG CCC CGG 
 





SCA2F-FAM FAM-GGG CCC CTC ACC ATG TCG 
SCA2R CGG GCT TGC CCA CAT TGG 
 
Supplementary Table S2   Primers used for standard PCR of ATXN2 repeat expansions. 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry
 doi: 10.1136/jnnp-2020-325014–9.:10 2021;J Neurol Neurosurg Psychiatry, et al. Shepheard SR
 2 
 
Gene RefSeq Transcript Gene RefSeq Transcript 
CHMP2B NM_014043.3 MATR3 NM_199189.2 
CYP27A1 NM_000784.3 NEFH NM_021076.3 
DCTN1 NM_004082.4 NEK1 NM_001199397.1 
GRN NM_002087.3 OPTN NM_001008211.1 
MAPT NM_005910.5 PFN1 NM_005022.3 
SPG11 NM_025137.1 PRPH NM_006262.3 
ALS2 NM_020919.3 SETX NM_015046.5 
ANG NM_001145.4 SIGMAR1 NM_005866.3 
ANXA11 NM_145869.1 SOD1 NM_000454.4 
ARHGEF28 NM_001080479.2 SPAST NM_014946.3 
ATXN2 NM_002973.3 SPG20 NM_015087.4 
C9orf72 NM_001256054.2 SQSTM1 NM_003900.4 
CHCHD10 NM_213720.2 SS18L1 NM_198935.2 
DAO NM_001917.4 TAF15 NM_139215.2 
ERBB4 NM_005235.2 TARDBP NM_007375.3 
EWSR1 NM_013986.3 TBK1 NM_013254.3 
FIG4 NM_014845.5 TUBA4A NM_006000.2 
FUS NM_004960.3 UBQLN2 NM_013444.3 
GBA2 NM_020944.2 VAPB NM_004738.4 
HNRNPA1 NM_031157.2 VCP NM_007126.3 
HNRNPA2B1 NM_031243.2 VPS54 NM_016516.2 
KIF5A NM_004984.2 VRK1 NM_003384.2 
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Supplementary Table S5.  Inclusion and exclusion criteria for the 




For all participants: 
• Age>18 
• Participant is willing and able to give informed consent for participation in the study, or 
an appropriate consultee can be identified to provide advice about his/her friend or 
relative’s inclusion in the study. If the participant is unable to provide written consent 
due to physical disability, an independent witness will be present at the informed 
consent discussion and sign the consent form on the participant’s behalf. 
Additional criterion for patients with MND only: 
• Diagnosis made by experienced neurologist. 
Additional criterion for family members of patients with MND only: 
• Known to have an MND gene mutation, or is a genetic relative of an affected MND or 
FTD patient.  
Additional criterion for patients with other neurological conditions only: 
• Diagnosis by a neurologist of another neurological condition, for example, Kennedy's 





The participant may not enter the study if ANY of the following apply: 
• Age <18 years 
• Pregnancy or any other condition that in the opinion of the investigator could interfere 
with the interpretation of the study results. 
In addition to the general inclusion/exclusion criteria described above, the additional 
exclusion criteria apply for invasive procedures (skin biopsy and lumbar puncture): 
• Significant bleeding diathesis or sepsis, or other condition that in the opinion of the 
investigator could constitute a health risk to the participant if he/she took part in this 
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Supplementary Figure S1   Gene Panel Coverage 
A. Mean coverage across the targeted region of the panel, error bars represent standard deviation. 
B. Percentage of targeted bases that are covered at greater than or equal to 100x. C. Percentage 
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Supplementary Figure S2   Contamination Estimate 
Samples are routinely checked for contamination as part of the clinical diagnostics pipeline using 
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Supplementary Figure S5 FIG4 Frameshift Variant 
A. Raw sequencing reads from SHF-065 show the presence of a heterozygous insertion in codon 
689 of FIG4 (NM_014845). B. Position of the frameshift mutation detected in the AMBRoSIA 
cohort vs the 5 frameshift variants present in ClinVar at the time of writing, 4/5 are classed as 
pathogenic. 
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Supplementary Figure S6 SPG20 Frameshift Variant 
A. Raw sequencing reads from SHF-148 show the presence of a heterozygous deletion in codon 
657 of SPG20 (NM_015087). B. Position of the frameshift mutation detected in the AMBRoSIA 
cohort vs the 4 frameshift variants present in ClinVar at the time of writing, 3/4 are classed as 
pathogenic. 
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Supplementary Figure S7 TBK1 Inframe Deletion Variant 
A. IGV plot showing a heterozygous 3bp deletion in codon 641 of TBK1. B. ProteinPaint of the 
TBK1 protein showing the deletion detected in this dataset (top) compared to deletions detected in 
ClinVar (bottom). Deletion in AMBRoSIA cohort is at the same position as a reported pathogenic 
mutation in ClinVar. 
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Supplementary Figure S8 Additional ProteinPaints of genes implicated in ALS 
Genes with at least 2 variants not already included in the manuscript and predicted to be 
Pathogenic/Likely Pathogenic or VUS were chosen for display here (excluding expansions). 
ProteinPaints were produced using https://pecan.stjude.cloud/proteinpaint and edited in Adobe 
Illustrator. 
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